title: Individualizing insulin therapy in the management of type 2 diabetes.
abstract: It is recognized that reducing hyperglycemia early on in disease progression has long-term benefits for patients with diabetes. Insulin therapy has greater potential to reduce hyperglycemia than other therapies; however, there is often a significant delay in insulin initiation and intensification. Insulin replacement therapy in type 2 diabetes should no longer be viewed as the treatment of last resort. With the development of modern insulin analogs, the field has evolved. Large clinical trials have improved our understanding of the potential benefits and risks associated with intensive glycemic control in different patient populations and highlighted the need for individualization of glycemic targets and treatment strategies. Current treatment guidelines recognize the important role of insulin therapy both early on and throughout the progression of type 2 diabetes.
authors.affiliation: Department of Medicine, University of California Los Angeles, Los Angeles, Calif. Electronic address: emoghissi@gmail.com.
authors.forename: Etie
authors.initials: E
authors.lastname: Moghissi
authors.affiliation: CA Diabetes Care Center, Salinas, Calif.
authors.forename: Allen B
authors.initials: AB
authors.lastname: King
mesh_terms: D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000628:therapy; D019468:Disease Management; D016903:Drug Monitoring / Q000379:methods / Q000592:standards; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D054795:Incretins / Q000378:metabolism; D007267:Injections; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D017410:Practice Guidelines as Topic; D057285:Precision Medicine; D061665:Time-to-Treatment / Q000592:standards
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin
keywords: Diabetes management; Glycemic target; Individualizing therapy; Insulin; Type 2 diabetes